{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T12:06:02Z","timestamp":1784635562190,"version":"3.55.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,21]]},"DOI":"10.7759\/cureus.113083","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:41:58Z","timestamp":1784634118000},"source":"Crossref","is-referenced-by-count":0,"title":["Effectiveness and Safety of Two Thrombopoietin Receptor Agonists: A Retrospective Cohort Study of Adults With Primary Immune Thrombocytopenia"],"prefix":"10.7759","author":[{"given":"Diego G","family":"Lanza","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo J","family":"Enciso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis G","family":"Moncaleano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mar\u00eda A","family":"Rodr\u00edguez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-019-53209-y","article-title":"Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia","volume":"9","author":"Lozano ML","year":"2019","unstructured":"Lozano ML, Mingot-Castellano ME, Perera MM, et al.. Deciphering predictive factors for choice of thrombopoietin receptor agonist, treatment free responses, and thrombotic events in immune thrombocytopenia. Sci Rep. 2019, 9:16680. 10.1038\/s41598-019-53209-y","journal-title":"Sci Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1007\/s44337-024-00040-8","article-title":"Immune thrombocytopenia: a review of pathogenesis and current treatment","volume":"1","author":"Yan X","year":"2024","unstructured":"Yan X, Yun Z, Tian L, et al.. Immune thrombocytopenia: a review of pathogenesis and current treatment. Dis Med. 2024, 1:57. 10.1007\/s44337-024-00040-8","journal-title":"Dis Med"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1053\/j.seminhematol.2014.10.006","article-title":"Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists","volume":"52","author":"Rodeghiero F","year":"2015","unstructured":"Rodeghiero F, Ruggeri M. Treatment of immune thrombocytopenia in adults: the role of thrombopoietin-receptor agonists. Semin Hematol. 2015, 52:16-24. 10.1053\/j.seminhematol.2014.10.006","journal-title":"Semin Hematol"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2008-07-162503","article-title":"Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group","volume":"113","author":"Rodeghiero F","year":"2009","unstructured":"Rodeghiero F, Stasi R, Gernsheimer T, et al.. Standardization of terminology, definitions and outcome criteria in immune thrombocytopenic purpura of adults and children: report from an international working group. Blood. 2009, 113:2386-93. 10.1182\/blood-2008-07-162503","journal-title":"Blood"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2019000966","article-title":"American Society of Hematology 2019 guidelines for immune thrombocytopenia","volume":"3","author":"Neunert C","year":"2019","unstructured":"Neunert C, Terrell DR, Arnold DM, et al.. American Society of Hematology 2019 guidelines for immune thrombocytopenia. Blood Adv. 2019, 3:3829-66. 10.1182\/bloodadvances.2019000966","journal-title":"Blood Adv"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2024000594","article-title":"Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy","volume":"2024","author":"Ghanima W","year":"2024","unstructured":"Ghanima W, Cuker A, Michel M. Insights on treatment of adult ITP: algorithm for management and role of multimodal therapy. Hematology Am Soc Hematol Educ Program. 2024, 2024:678-84. 10.1182\/hematology.2024000594","journal-title":"Hematology Am Soc Hematol Educ Program"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1007\/s00277-023-05114-8","article-title":"Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus","volume":"102","author":"Pulani\u0107 D","year":"2023","unstructured":"Pulani\u0107 D, B\u00e1torov\u00e1 A, Bod\u00f3 I, et al.. Use of thrombopoietin receptor agonists in adults with immune thrombocytopenia: a systematic review and Central European expert consensus. Ann Hematol. 2023, 102:715-27. 10.1007\/s00277-023-05114-8","journal-title":"Ann Hematol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMct1014202","article-title":"Thrombopoietin-receptor agonists for primary immune thrombocytopenia","volume":"365","author":"Imbach P","year":"2011","unstructured":"Imbach P, Crowther M. Thrombopoietin-receptor agonists for primary immune thrombocytopenia. N Engl J Med. 2011, 365:734-41. 10.1056\/NEJMct1014202","journal-title":"N Engl J Med"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60203-2","article-title":"Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial","volume":"371","author":"Kuter DJ","year":"2008","unstructured":"Kuter DJ, Bussel JB, Lyons RM, et al.. Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial. Lancet. 2008, 371:395-403. 10.1016\/S0140-6736(08)60203-2","journal-title":"Lancet"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.12260","article-title":"Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy","volume":"161","author":"Kuter DJ","year":"2013","unstructured":"Kuter DJ, Bussel JB, Newland A, et al.. Long-term treatment with romiplostim in patients with chronic immune thrombocytopenia: safety and efficacy. Br J Haematol. 2013, 161:411-23. 10.1111\/bjh.12260","journal-title":"Br J Haematol"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(10)60959-2","article-title":"Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study","volume":"377","author":"Cheng G","year":"2011","unstructured":"Cheng G, Saleh MN, Marcher C, et al.. Eltrombopag for management of chronic immune thrombocytopenia (RAISE): a 6-month, randomised, phase 3 study. Lancet. 2011, 377:393-402. 10.1016\/S0140-6736(10)60959-2","journal-title":"Lancet"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2012-04-425512","article-title":"Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study","volume":"121","author":"Saleh MN","year":"2013","unstructured":"Saleh MN, Bussel JB, Cheng G, Meyer O, Bailey CK, Arning M, Brainsky A. Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study. Blood. 2013, 121:537-45. 10.1182\/blood-2012-04-425512","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1080\/16078454.2019.1568659","article-title":"Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis","volume":"24","author":"Yang R","year":"2019","unstructured":"Yang R, Lin L, Yao H, Ji O, Shen Q. Therapeutic options for adult patients with previously treated immune thrombocytopenia - a systematic review and network meta-analysis. Hematology. 2019, 24:290-9. 10.1080\/16078454.2019.1568659","journal-title":"Hematology"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0198504","article-title":"Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis","volume":"13","author":"Zhang J","year":"2018","unstructured":"Zhang J, Liang Y, Ai Y, et al.. Eltrombopag versus romiplostim in treatment of adult patients with immune thrombocytopenia: a systematic review incorporating an indirect-comparison meta-analysis. PLoS One. 2018, 13:e0198504. 10.1371\/journal.pone.0198504","journal-title":"PLoS One"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2018.212845","article-title":"Thrombopoietin receptor agonists: ten years later","volume":"104","author":"Ghanima W","year":"2019","unstructured":"Ghanima W, Cooper N, Rodeghiero F, Godeau B, Bussel JB. Thrombopoietin receptor agonists: ten years later. Haematologica. 2019, 104:1112-23. 10.3324\/haematol.2018.212845","journal-title":"Haematologica"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24935","article-title":"Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers","volume":"93","author":"Cantoni S","year":"2018","unstructured":"Cantoni S, Carpenedo M, Mazzucconi MG, et al.. Alternate use of thrombopoietin receptor agonists in adult primary immune thrombocytopenia patients: a retrospective collaborative survey from Italian hematology centers. Am J Hematol. 2018, 93:58-64. 10.1002\/ajh.24935","journal-title":"Am J Hematol"},{"key":"ref17","article-title":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision","year":"2016","unstructured":"International Statistical Classification of Diseases and Related Health Problems, 10th Revision. World Health Organization, Geneva; 2016."},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbi.2008.08.010","article-title":"Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support","volume":"42","author":"Harris PA","year":"2009","unstructured":"Harris PA, Taylor R, Thielke R, Payne J, Gonzalez N, Conde JG. Research electronic data capture (REDCap)--a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009, 42:377-81. 10.1016\/j.jbi.2008.08.010","journal-title":"J Biomed Inform"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1185\/03007995.2011.644849","article-title":"Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia","volume":"28","author":"Fogarty PF","year":"2012","unstructured":"Fogarty PF, Tarantino MD, Brainsky A, Signorovitch J, Grotzinger KM. Selective validation of the WHO Bleeding Scale in patients with chronic immune thrombocytopenia. Curr Med Res Opin. 2012, 28:79-87. 10.1185\/03007995.2011.644849","journal-title":"Curr Med Res Opin"},{"key":"ref20","article-title":"R: A Language and Environment for Statistical Computing","year":"2025","unstructured":"R. A Language and Environment for Statistical Computing. R Foundation for Statistical Computing, Vienna, Austria; 2025."},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1016\/0021-9681(87)90171-8","article-title":"A new method of classifying prognostic comorbidity in longitudinal studies: development and validation","volume":"40","author":"Charlson ME","year":"1987","unstructured":"Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987, 40:373-83. 10.1016\/0021-9681(87)90171-8","journal-title":"J Chronic Dis"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2025.1667457","article-title":"Bridging the gaps between randomized controlled trials and real-world use of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: a systematic review and meta-analysis","volume":"12","author":"Luo L","year":"2025","unstructured":"Luo L, Jin S, Song Z, et al.. Bridging the gaps between randomized controlled trials and real-world use of thrombopoietin receptor agonists for adult primary immune thrombocytopenia: a systematic review and meta-analysis. Front Med (Lausanne). 2025, 12:1667457. 10.3389\/fmed.2025.1667457","journal-title":"Front Med (Lausanne)"},{"key":"ref23","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2016.146373","article-title":"Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome","volume":"101","author":"Grimaldi-Bensouda L","year":"2016","unstructured":"Grimaldi-Bensouda L, Nordon C, Michel M, et al.. Immune thrombocytopenia in adults: a prospective cohort study of clinical features and predictors of outcome. Haematologica. 2016, 101:1039-45. 10.3324\/haematol.2016.146373","journal-title":"Haematologica"},{"key":"ref24","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.26378","article-title":"Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment","volume":"97","author":"Mageau A","year":"2022","unstructured":"Mageau A, Terriou L, Ebbo M, et al.. Splenectomy for primary immune thrombocytopenia revisited in the era of thrombopoietin receptor agonists: new insights for an old treatment. Am J Hematol. 2022, 97:10-7. 10.1002\/ajh.26378","journal-title":"Am J Hematol"},{"key":"ref25","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.24310","article-title":"Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years","volume":"91","author":"Palandri F","year":"2016","unstructured":"Palandri F, Polverelli N, Sollazzo D, Romano M, Catani L, Cavo M, Vianelli N. Have splenectomy rate and main outcomes of ITP changed after the introduction of new treatments? A monocentric study in the outpatient setting during 35 years. Am J Hematol. 2016, 91:E267-72. 10.1002\/ajh.24310","journal-title":"Am J Hematol"},{"key":"ref26","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1002625","article-title":"Romiplostim or standard of care in patients with immune thrombocytopenia","volume":"363","author":"Kuter DJ","year":"2010","unstructured":"Kuter DJ, Rummel M, Boccia R, et al.. Romiplostim or standard of care in patients with immune thrombocytopenia. N Engl J Med. 2010, 363:1889-99. 10.1056\/NEJMoa1002625","journal-title":"N Engl J Med"},{"key":"ref27","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2012.074633","article-title":"A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia","volume":"98","author":"Khellaf M","year":"2013","unstructured":"Khellaf M, Viallard JF, Hamidou M, et al.. A retrospective pilot evaluation of switching thrombopoietic receptor-agonists in immune thrombocytopenia. Haematologica. 2013, 98:881-7. 10.3324\/haematol.2012.074633","journal-title":"Haematologica"},{"key":"ref28","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19345","article-title":"Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: results from the TRAIT study","volume":"204","author":"Cooper N","year":"2024","unstructured":"Cooper N, Scully M, Percy C, et al.. Real-world use of thrombopoietin receptor agonists for the management of immune thrombocytopenia in adult patients in the United Kingdom: results from the TRAIT study. Br J Haematol. 2024, 204:2442-52. 10.1111\/bjh.19345","journal-title":"Br J Haematol"},{"key":"ref29","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-021-01727-5","article-title":"Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic immune thrombocytopenia in European clinical practice","volume":"38","author":"Snell Taylor SJ","year":"2021","unstructured":"Snell Taylor SJ, Nielson CM, Breskin A, et al.. Effectiveness and safety of romiplostim among patients with newly diagnosed, persistent and chronic immune thrombocytopenia in European clinical practice. Adv Ther. 2021, 38:2673-88. 10.1007\/s12325-021-01727-5","journal-title":"Adv Ther"},{"key":"ref30","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022008287","article-title":"Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE","volume":"7","author":"Wong RS","year":"2023","unstructured":"Wong RS, Yava\u015fo\u011flu \u0130, Yassin MA, et al.. Eltrombopag in patients with chronic immune thrombocytopenia in Asia-Pacific, the Middle East, and Turkey: final analysis of CITE. Blood Adv. 2023, 7:4773-81. 10.1182\/bloodadvances.2022008287","journal-title":"Blood Adv"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/387103-effectiveness-and-safety-of-two-thrombopoietin-receptor-agonists-a-retrospective-cohort-study-of-adults-with-primary-immune-thrombocytopenia","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:41:59Z","timestamp":1784634119000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/387103-effectiveness-and-safety-of-two-thrombopoietin-receptor-agonists-a-retrospective-cohort-study-of-adults-with-primary-immune-thrombocytopenia"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,21]]},"references-count":30,"URL":"https:\/\/doi.org\/10.7759\/cureus.113083","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,21]]}}}